Most patients with hematologic malignancies receive what is conventionally classified as aggressive care in their final days, yet the intensity of that care does not appear to determine how well they die, according to a new multicenter study published in BMC Palliative Care.
The retrospective mortality follow-back cohort included 644 adult hemato-oncology decedents across four medical centers. Using a traditional dichotomous approach, the researchers classified 87.3 percent of patients as having received aggressive end-of-life care. However, a continuous composite score ranging from 0 to 6 told a more nuanced story: the median score was 2.0, with a mean of 2.13 and a standard deviation of 1.33, and almost 60 percent of decedents had accumulated two or fewer interventions. Overall, 71.9 percent of patients died in a hospital setting.
The gap between these two measurement approaches is central to the study’s findings. A binary label of aggressive care can mask substantial variation in how many interventions a patient actually received, and the composite score suggests that many patients classified as receiving aggressive care experienced relatively few end-of-life procedures.
To capture the subjective side of dying, the team conducted a prospective quantitative substudy of 45 primary caregivers, who were interviewed after the patient’s death using the validated Quality of Dying and Death questionnaire. In this caregiver subsample, the mean overall QODD score was moderate at 62.53, with a standard deviation of 10.57.
Bivariate analysis revealed no statistically significant correlation between the continuous care aggressiveness score and overall QODD ratings.
The authors caution that these are exploratory, preliminary findings from a single cohort. In their conclusions, they note that no statistically significant association was detected between objective care aggressiveness scores and subjective caregiver appraisals, and they emphasize that larger studies are needed to determine whether objective utilization and subjective experience represent distinct, multidimensional facets of end-of-life care in this population.
The study’s authors also raise questions about frameworks originally developed for solid tumors being applied uncritically to hematologic malignancies. In blood cancers, they argue, acute interventions often reflect essential supportive stabilization rather than therapeutic excess, because unpredictable disease courses and acute supportive care needs make evaluating the quality of dying and death in this population particularly complex.
By highlighting the value of considering disease-specific supportive demands, the findings suggest that standard measures of end-of-life care aggressiveness may not directly capture the unique clinical realities of hematologic malignancies. The researchers encourage future large-scale studies to explore the relationship between objective measures of care and the subjective experiences of patients and families at the end of life.
Subject of Research: End-of-life care aggressiveness and quality of dying and death in hemato-oncology
Article Title: End-of-life care aggressiveness and quality of death and dying in hemato-oncology
Article References: Braun, M., Shaulov, A., Bergman, M., Lichtenfeld, G., Hellmann, I., Tadmor, T., Bonneh, N., Rado, S., & Aviv, A. (2026). End-of-life care aggressiveness and quality of death and dying in hemato-oncology. BMC Palliative Care. https://doi.org/10.1186/s12904-026-02397-2
Image Credits: AI Generated
DOI: 10.1186/s12904-026-02397-2
Keywords: hemato-oncology, end-of-life care, care aggressiveness, quality of dying and death, QODD, palliative care, hematologic malignancies, caregivers, hospital death, mortality follow-back, End-of-life, care
News Source: Nathaniel Bowman. (October 29, 2026). Aggressive end-of-life care common in blood cancers, but intensity may not shape dying quality. Scienmag.
